Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 15/20 | 0.53 |
| ▸ | ROCK1 | Q13464 | 13/20 | 0.53 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21217790 | 1.00 | ROCK2 (0.53) | ROCK2ROCK1SYKMEN1KMT2A | |
| SCHEMBL24610411 | 0.92 | ROCK2 (0.49) | ROCK2ROCK1SYKMEN1KMT2A | |
| SCHEMBL21217529 | 0.91 | ROCK2 (0.51) | ROCK2ROCK1SYKPOLBSMYD3 | |
| SCHEMBL24610385 | 0.91 | ROCK2 (0.49) | ROCK2ROCK1SYKPOLBSMYD3 | |
| SCHEMBL21217793 | 0.87 | ROCK2 (0.43) | ROCK2ROCK1SYK | |
| SCHEMBL24610384 | 0.85 | ROCK2 (0.47) | ROCK2ROCK1MEN1KMT2ANPC1 | |
| SCHEMBL22967219 | 0.85 | ROCK2 (0.61) | ROCK2ROCK1MEN1KMT2ANPC1 | |
| SCHEMBL21217861 | 0.85 | ROCK2 (0.61) | ROCK2ROCK1MEN1KMT2ANPC1 | |
| SCHEMBL22966751 | 0.85 | ROCK2 (0.61) | ROCK2ROCK1MEN1KMT2ANPC1 | |
| SCHEMBL24094285 | 0.83 | NPC1 (0.40) | ROCK2ROCK1MEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3743420-B1 | HETEROCYCLYLAMINO-SUBSTITUTED TRIAZOLES AS MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | REDX PHARMA PLC (GB) | 2021-12-15 | — | — | EP | disclosed |